The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer ...
Dec 6, 2020
0
5
A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer ...
Dec 5, 2020
0
187
Clonal hematopoiesis (CH) is a recently identified condition in which mutations associated with blood cancers are detected in the blood of some healthy, usually older, individuals who don't have cancer. People with CH, while ...
Dec 5, 2020
0
28
For scientists hoping to harness a powerful new technique for demolishing cellular enzymes known as kinases, the choices can be a bit overwhelming. Some 514 different protein kinases toil in human cells, representing 2.5% ...
Dec 3, 2020
0
31
Mortality rates after cancer surgery declined for Black as well as white patients during a recent ten-year period, although the mortality gap between the two groups did not narrow, according to new research by Dana-Farber ...
Dec 3, 2020
0
9
In states that have expanded Medicaid availability as part of the Affordable Care Act (ACA), mortality rates for three major forms of cancer are significantly lower than in states that have not expanded their Medicaid, a ...
Nov 5, 2020
0
0
A novel agent that targets a mutated form of the KRAS gene—the most commonly altered oncogene in human cancers and one long considered "undruggable"—shrank tumors in most patients in a clinical trial with manageable side ...
Oct 25, 2020
0
17
Scientists have created an unprecedented 3-dimensional structural model of a key molecular "machine" known as the BAF complex, which modifies DNA architecture and is frequently mutated in cancer and some other diseases. The ...
Oct 13, 2020
0
16
The COVID-19 pandemic has impacted virtually every aspect of cancer care and research- from introducing new risks for cancer patients to disrupting the delivery of cancer treatment and the continuity of cancer research, a ...
Oct 6, 2020
0
2
Adding an immunotherapy agent to a three-drug chemotherapy regimen can improve the likelihood that early-stage triple-negative breast cancer will recede to undetectable levels, data from a clinical trial led by Dana-Farber/Brigham ...
Sep 21, 2020
0
4
